Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Rani Therapeutics Holdings, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 ANNOUNCED STRATEGIC RESEARCH COLLABORATION WITH CHUGAI FOR TWO UNDISCLOSED MOLECULES   PRESENTED PRECLINICAL DATA DEMONSTRATING BIOEQUIVALENCE OF NOVEL, BISPECIFIC GLP-1/GLP-2 RECEPTOR AGONIST DELIVERED ORALLY VIA RANIPILL (RT-114) COMPARED TO SUBCUTANEOUS DELIVERY AT ENDO 2025   PHASE 1 STUDY FOR RT-114 FOR THE TREATMENT OF OBESITY EXPECTED TO INITIATE IN THE SECOND HALF OF 2025   ANNOUNCED A WARRANT INDUCEMENT TRANSACTION WITH AN EXISTING INVESTOR WITH GROSS PROCEEDS OF $4.3 MILLION   ANNOUNCED PRICING OF $3.0 MILLION REGISTERED DIRECT OFFERING  SAN JOSE, CALIF., AUG. 07, 2025 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS OR RANI) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025 AND PROVIDED A CORPORATE UPDATE.

RANI THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS; PROVIDES CORPORATE UPDATE

SAN JOSE, CALIF., JULY 15, 2025 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS OR RANI) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH A SINGLE INSTITUTIONAL INVESTOR FOR THE PURCHASE AND SALE OF 4,354,000 SHARES OF RANI THERAPEUTICS' CLASS A COMMON STOCK AT A PURCHASE PRICE OF$0.40 PER SHARE AND PRE-FUNDED WARRANTS TO PURCHASE 3,146,000 SHARES OF CLASS A COMMON STOCK AT A PURCHASE PRICE OF$0.3999 IN A REGISTERED DIRECT OFFERING. THE EXERCISE PRICE OF EACH PRE-FUNDED WARRANT IS $0.0001 PER SHARE OF CLASS A COMMON STOCK.

RANI THERAPEUTICS HOLDINGS, INC. ANNOUNCES PRICING OF $3.0 MILLION REGISTERED DIRECT OFFERING

SAN JOSE, CALIF., JULY 14, 2025 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS OR RANI) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY ANNOUNCED THAT IT WILL PRESENT PRECLINICAL DATA ON THE RANIPILL CAPSULE AT THE ENDOCRINE SOCIETY'S ANNUAL MEETING (ENDO 2025) TAKING PLACE JULY 12-15 IN SAN FRANCISCO, CA.

RANI THERAPEUTICS AND PROGEN ANNOUNCE LATE BREAKING PRESENTATION AT ENDO 2025 DEMONSTRATING BIOEQUIVALENCE OF NOVEL, BISPECIFIC GLP-1/GLP-2 RECEPTOR AGONIST DELIVERED ORALLY VIA RANIPILL COMPARED TO SUBCUTANEOUS DELIVERY

- RESEARCHAGREEMENT IS EVALUATING FEASIBILITY OF APPLYING RANI'S ORAL DELIVERY TECHNOLOGY TO CHUGAI'S ANTIBODIES AGAINST UNDISCLOSED TARGETS - SAN JOSE, CALIF., MAY 19, 2025 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS OR RANI) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY ANNOUNCED THE COMPANY HAS ENTERED INTO A RESEARCH AGREEMENT ON 13TH AUGUST, 2024, FOR TWO MOLECULES WITH UNDISCLOSED TARGETS PROVIDED BY CHUGAI PHARMACEUTICAL CO., LTD.

RANI THERAPEUTICS ANNOUNCES RESEARCH AGREEMENT WITH CHUGAI

- ANNOUNCED PRECLINICAL DATA DEMONSTRATING THE BIOEQUIVALENCE OF RT-114, A BISPECIFIC GLP-1/GLP-2 RECEPTOR AGONIST (PG-102), DELIVERED ORALLY VIA THE RANIPILL CAPSULE, TO SUBCUTANEOUS ADMINISTRATION OF PG-102 -

RANI THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS; PROVIDES CORPORATE UPDATE

- ANNOUNCED PRECLINICAL DATA DEMONSTRATING THE BIOEQUIVALENCE OF RT-114, A GLP-1/GLP-2 DUAL AGONIST (PG-102) DELIVERED ORALLY VIA THE RANIPILL CAPSULE, TO SUBCUTANEOUS ADMINISTRATION OF PG-102 -

RANI THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS; PROVIDES CORPORATE UPDATE

- RT-114 YIELDED A RELATIVE BIOAVAILABILITY OF 111% COMPARED TO PG-102 DELIVERED SUBCUTANEOUSLY WITH COMPARABLE PK PROFILES, MEETING THE PRIMARY ENDPOINT OF DEMONSTRATING BIOEQUIVALENC E 

RANI THERAPEUTICS ANNOUNCES PRECLINICAL DATA DEMONSTRATING BIOEQUIVALENCE OF RT-114, A GLP-1/GLP-2 DUAL AGONIST (PG-102) DELIVERED ORALLY VIA THE RANIPILL CAPSULE, TO SUBCUTANEOUSLY ADMINISTERED PG-102

SAN JOSE, CALIF., MARCH 25, 2025 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS OR RANI) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY ANNOUNCED THAT IT PLANS TO RELEASE FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2024 AND PROVIDE A BUSINESS UPDATE ON MONDAY, MARCH 31, 2025 AFTER THE CLOSE OF TRADING. RANI'S MANAGEMENT TEAM WILL HOST A CONFERENCE CALL AND WEBCAST BEGINNING AT 4:30 P.M. ET.

RANI THERAPEUTICS TO REPORT FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

SAN JOSE, CALIF., OCT. 15, 2024 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS OR RANI) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH A SINGLE INSTITUTIONAL INVESTOR FOR THE PURCHASE AND SALE OF 3,000,000 SHARES OF RANI THERAPEUTICS' CLASS A COMMON STOCK (THE COMMON STOCK) AND PRE-FUNDED WARRANTS TO PURCHASE 333,333 SHARES OF COMMON STOCK, TOGETHER WITH SERIES C COMMON WARRANTS TO PURCHASE UP TO AN AGGREGATE OF 3,333,333 SHARES OF COMMON STOCK, IN A REGISTERED DIRECT OFFERING. EACH SHARE OF COMMON STOCK (OR PRE-FUNDED WARRANT) IS BEING SOLD TOGETHER WITH ONE SERIES C COMMON WARRANT AT A COMBINED PURCHASE PRICE OF$3.00. THE SERIES C COMMON WARRANTS WILL HAVE AN EXERCISE PRICE OF$3.00PER SHARE AND WILL EXPIRE 5 YEARS FROM THE DATE OF ISSUANCE.

RANI THERAPEUTICS HOLDINGS, INC. ANNOUNCES PRICING OF $10.0 MILLION REGISTERED DIRECT OFFERING AND CANCELLATION OF CERTAIN EXISTING WARRANTS

SAN JOSE, CALIF., OCT. 08, 2024 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS OR RANI) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY ANNOUNCED THAT THE COMPANY'S CHIEF EXECUTIVE OFFICER, TALAT IMRAN, AND CHIEF FINANCIAL OFFICER, SVAI SANFORD, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 2024 MAXIM HEALTHCARE VIRTUAL SUMMIT ON THURSDAY, OCTOBER 17, 2024 FROM 11:30 AM  12:00 PM E.T. IN TRACK 2.

Rani Therapeutics Holdings, Inc.

RANI

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Rani Therapeutics Holdings, Inc.

RANI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RANI